Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases.
Meiss
F
F
Helmbold
P
P
Meykadeh
N
N
Gaber
G
G
Marsch
W Ch
WCh
Fischer
M
M
D000208:Acute Disease; D000328:Adult; D000658:Amoxicillin / Q000009:adverse effects; D000667:Ampicillin / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002981:Clindamycin / Q000009:adverse effects; D003879:Dermatologic Agents / Q000627:therapeutic use*; D003875:Drug Eruptions / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced* / Q000188:drug therapy*; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy* / Q000209:etiology*; D013407:Sulbactam / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D002981:Clindamycin; D000667:Ampicillin; D000658:Amoxicillin; D000069285:Infliximab; D013407:Sulbactam